HLB’s liver cancer drug faces an FDA request for additional information, 7 month 10 day, all group stocks hit the lower price limit
After the U.S. Food and Drug Administration (FDA) requested additional information about HLB’s liver cancer drug, 7 month 10 day, HLB and its affiliates hit the lower price limit during trading. Over the same period, Emart’s target price was 15% lowered due to sluggish Starbucks sales, while some large-cap stocks and leveraged products drew 83% of trading value, according to criticism.
After it was confirmed that HLB’s liver cancer drug had received a request for additional information from the U.S. Food and Drug Administration (FDA), 7 month 10 day, HLB and its group affiliates hit the lower price limit during trading. The emergence of a regulatory issue related to the clinical approval process was directly perceived as either favorable or unfavorable news.
7 month 9 day, HLB’s share price had also plunged amid related uncertainty, and 7 month 10 day, reports continued that group stocks had collectively hit the lower price limit following additional news.
The company confirmed that the FDA had requested additional information. The specific items requiring supplementation and the submission deadline were not disclosed.
During the same period, E-Mart lowered its target price by 15%. The news heightened concerns about performance in the retail sector.
Market participants observed that trading value was concentrated in certain large-cap stocks and leveraged products, with 83% of total trading value skewed toward one side.
Subsequently, major related stocks posted sharp intraday declines that day. Volatility may continue as additional disclosures and announcements are released.